key: cord-0907267-0aciidcq authors: Al‐Mashdali, Abdulrahman F.; Ata, Yaser M.; Yassin, Mohamed A. title: Concomitant autoimmune hemolytic anemia and pulmonary embolism associated with mild COVID‐19: A case report date: 2021-10-18 journal: Clin Case Rep DOI: 10.1002/ccr3.4952 sha: 9168c1d69c5bfacedaddbd0e9d631a556e680aef doc_id: 907267 cord_uid: 0aciidcq Despite its rarity, AIHA can be associated with COVID‐19. It should be suspected in a patient with recent COVID‐19 presenting with unexplained anemia. Autoimmune hemolytic anemia (AIHA) is a rare immunemediated complication of COVID-19, leading to adverse clinical outcomes. The clinician should consider AIHA in any patient with current or recent COVID-19 developing unexplained normocytic anemia. In addition, pulmonary embolism might complicate AIHA and should also be investigated if clinically suspected. Autoimmune hemolytic anemia (AIHA) is acquired hemolytic anemia caused by the host's immune system attacking its red blood cells. 1 Different immunological processes are involved in the pathophysiology of AIHA, including autoantibodies, complement system, and cellmediated cytotoxicity. 2 There are four types of AIHA: warm autoimmune hemolytic anemia (wAIHA), cold agglutinin disease (CAD), mixed type AIHA (mixed AIHA), and paroxysmal cold hemoglobinuria (PCH). Direct antiglobulin test (DAT)is the gold standard for the diagnosis of AIHA, basically, by detecting the attached immunoglobulins to erythrocytes. 3 AIHA is a primary disease in around 50% of the cases, and in the remaining cases, it is associated with autoimmune diseases, lymphoproliferative disorders, infections, and solid tumors. 4 COVID-19 is an emerging systemic disease that has been associated with various complications, including autoimmune disorders and hypercoagulability. A limited number of AIHA cases have been reported in patients with SARS-CoV-2 infection, mainly associated with severe COVID-19 cases. 5 However, AIHA occurring with mild COVID-19 is an extremely unusual association and might be missed if not highly considered. 6 Herein, we report a patient who developed concurrent AIHA and pulmonary embolism (PE) after approximately two weeks of a mild COVID-19 infection. Up to the best of our knowledge, this is the first reported case of simultaneous AIHA and PE after a mild COVID-19. A 39-year-old Indian male with no significant past medical history presented to the emergency department (ED) on April 13, 2021, with fever and cough for three days. He was vitally stable and maintaining oxygen saturation on room air. After that, he tested positive for COVID-19; and there was no infiltrate on the chest X-ray ( Figure 1A) . Accordingly, he was diagnosed as a case of mild COVID-19, which was treated conservatively and stayed in the quarantine facility for one week and discharged after that. He only received paracetamol and multivitamin tablets during his quarantine period. On May 6, 2021, he presented to the ED with progressive shortness of breath (SOB), cough, and chest pain for ten days. In ED, he was afebrile and had a respiratory rate of 25 breaths/min, pulse rate of 120 beats/min, blood pressure of 110/75 mmHg, and oxygen saturation of 96% on room air. Physical examination was significant for a bilateral decrease of air entry in the lung bases, and apart from that, the examination was unremarkable. Electrocardiography (ECG) revealed sinus tachycardia without features of pulmonary embolism, and CXR demonstrated patchy infiltrates in the lower zones bilaterally and blunting of the costophrenic angles suggestive of pleural effusions ( Figure 2B ). Repeated COVID-19 polymerase chain reaction (PCR) was negative. His laboratory investigations revealed a hemoglobin level of 8.2 gm/dl (his hemoglobin level was 16.4 gm/ dl when he was diagnosed with COVID-19) with normal mean corpuscular volume(MCV),elevated reticulocytes percentage (4.9%), high lactate dehydrogenase level (310 U/L), mildly elevated indirect bilirubin level (32 umol/L),normal haptoglobin,and D-dimer of 7.2 mg/L (normal <0.45). All relevant laboratory data are shown in Table 1 . He denied blackish discoloration of stool (melena), bleeding per rectum, or any bleeding from other body sites. Also, he denied a previous history of anemia or a family history of blood disorders. Accordingly, hemolytic anemia was suspected, and an extensive hemolysis workup was sent to look for the possible etiology. Notably, the tachycardia did not resolve (ranging from 110 to 120), although he received a vigorous amount of intravenous fluid. So, given his history of recent COVID-19 and current clinical findings (SOB, chest pain, tachypnea, and tachycardia), computed tomographic pulmonary angiography (CTPA) was requested to exclude pulmonary embolism. CTPA revealed bilateral pulmonary emboli, in addition to lung bases consolidation and pleural effusion ( Figure 2 ). N-terminal pro-b-type natriuretic peptide (NTproBNP) and high-sensitivity cardiac troponin were not elevated. Echocardiography was unremarkable (no signs of right ventricular strain or dysfunction). Subsequently, the patient was started on a therapeutic dose of enoxaparin (60 mg twice daily). Regarding hemolytic anemia investigations, peripheral blood smear demonstrated normocytic normochromic anemia with polychromasia, rouleaux, and anisopoikilocytosis, including scattered spherocytes. Serum iron profile, folate, and vitamin B12 level were within normal ranges. Glucose-6-phosphate dehydrogenase (G6PD) deficiency screening and hemoglobin electrophoresis (to rule out hemoglobinopathies) were normal. Testing for hepatotropic viruses, human immunodeficiency virus (HIV), Epstein-Barr virus (EBV), cytomegalovirus (CMV), parvovirus B19, respiratory viruses, and mycoplasma pneumonia were negative. In addition, antinuclear antibody (ANA) and antineutrophil cytoplasmic antibodies (ANCA) results came negative. However, DAT was strongly positive for immunoglobulin G (IgG) and negative for both IgM and C3d. Abdominal ultrasound (AUS) was unremarkable (did not show evidence of organomegaly). Hence, the diagnosis of AIHA, most likely associated with COVID-19 was made, and the patient started on prednisolone (60 mg daily). He was asymptomatic at day eight of the hospital stay, vitally stable (tachycardia resolved), and his hemoglobin level improved to 11.4 gm/dl. He was discharged on rivaroxaban for PE and a tapering dose of prednisolone for AIHA on day nine. Unfortunately, he lost follow-up at the outpatient clinic because he had traveled to his home country. SARS-CoV 2 infection has been recently linked to the development of AIHA. Both warm AIHA (wAIHA) and cold AIHA (cAIHA) have been reported in patients with COVID-19. 5 Based on one review, only 20 cases of COVID-19-related AIHA are found in the literature. The average time between the onset of COVID-19 symptoms to the development of AIHA is around eight days. 7 Of note, most patients who developed AIHA had a moderate-severe COVID-19, and the inflammatory markers were notably elevated 7,8 ; however, AIHA can occur even in patients with asymptomatic COVID-19. 6 Moreover, a few of those patients had preexisting comorbidities, such as chronic lymphatic leukemia idiopathic thrombocytopenic purpura, or lymphomas, suggesting a possible underlying immunological phenomenon. 8 The pathophysiology of COVID-19 related AIHA is still not well-understood. At the beginning of the COVID-19 era, given that most of the AIHA events were associated with severe cases, it has been postulated that dysregulated immune system activation could be the likely cause through attacking of the red blood cells resulting in their hemolysis. However, this hypothesis did not explain the occurrence of AIHA in patients with mild or asymptomatic COVID-19 in the absence of hyperinflammatory response. Subsequently, a new hypothesis suggests that molecular mimicry between Ankyrin 1 (an erythrocyte membrane protein) and Spike protein (SARS-CoV-2 surface glycoprotein) could be the culprit in AIHA development in COVID-19 patients. 9, 10 The evidence for the treatment of COVID-19-related AIHA is scarce and based mainly on the reported cases, although glucocorticoid therapy has been shown to be very effective and most of the cases improved dramatically after commencing glucocorticoid therapy. [5] [6] [7] [8] Despite its rarity, AIHA is currently a wellrecognized risk factor for venous thromboembolism (VTE). However, this risk might be underestimated by many physicians. In a large observational study done in 2014 by Yusuf et al. 11 it was found that the odds ratio for VTE in patients with AIHA is approximately 1.25 (95% CI: 1.05-1.49) either during or before hospitalization. Interestingly, most of the VTE events in patients with AIHA happened in outpatient's settings with the absence of classic risk factors for venous thrombosis. Also, it was observed that these thrombotic events occurred almost always during active hemolytic attack. 12 The pathophysiology of hypercoagulability in AIHA patients is complex and multifactorial, triggered by both hemolysis and immune system effect. It has been proposed that the RBC membrane is modified through the attachment of autoantibodies, which enhancing the activation of clotting factors, especially prothrombin and factor X. Moreover, microparticles (MPs) and cell-free hemoglobin, which are released during hemolysis, can lead to oxidative stress on vascular endothelium, enhance thrombin synthesis, and facilitate platelet aggregation. Finally, glucocorticoids therapy might play a role in the pathogenesis of VTE in patients with AIHA. [12] [13] [14] Our patient started to develop the manifestations of AIHA almost two weeks after COVID-19. We believe that our case is interesting from different aspects. Initially, AIHA developed after a mild COVID-19, whereas the vast majority of COVID-19 related AIHA occurred in severe cases. Also, our patient did not have any comorbid condition, which was found in the majority of COVID-19 related AIHA cases, and associated with severe COVID-19. [15] [16] [17] Additionally, the hemolysis ensued after a lag period of two weeks, supporting the hypothesis of molecular mimicry as the most likely pathophysiology of AIHA in our patient. In addition to AIHA, concurrent multisegmental PE was diagnosed in our patient. We think that COVID-19 is unlikely to be the predisposing factor for hypercoagulability in our patient because it was only a mild infection (the patient did not require any oxygen support) with mildly elevated inflammatory markers. Accordingly, we contemplate that AIHA (with approximately 50% drop in hemoglobin level) was the predisposing factor for PE in our patient. COVID-19-related AIAH is increasingly reported in the literature. It should be highly considered in any COVID-19 patient who develops unexplained anemia, especially if it occurs within the first few weeks of the infection. Prompt management is pivotal to decrease morbidity and mortality of such condition. Given that AIHA might occur after patient discharge from the hospital or quarantine facility, we suggest for follow-up complete blood count within 2-4 weeks of COVID-19 to catch this disease in the early stage. In addition, based on our case, we recommend having a lower threshold for PE diagnosis in a patient with AIHA, especially in the presence of significant dyspnea or persistent tachycardia. The authors would like to acknowledge Qatar national library (QNL) for this publication's funding and the HMC internal medicine residency program for scientific support. The authors have no conflict of interest to declare. AFA contributed to patient care, data collection, literature review, and manuscript writing. YMA contributed to data collection and manuscript writing. MAY contributed to the final manuscript review and editing. All authors reviewed and approved the final version of the article. This case report was approved by the Hamad Medical Corporation's Medical Research Center (Protocol number: MRC-04-21-581). Written informed consent was obtained from the patient for the publication of this case report. The datasets used and/or analyzed during the current study are available from the corresponding author on request. Abdulrahman F. Al-Mashdali https://orcid. org/0000-0002-1393-5302 Yaser M. Ata https://orcid.org/0000-0001-6261-0523 Autoimmune hemolytic anemia Autoimmune hemolytic anemia: current knowledge and perspectives Current and emerging treatment options for autoimmune hemolytic anemia Mycoplasma pneumoniae associated with severe autoimmune hemolytic anemia: case report and literature review Autoimmune haemolytic anaemia associated with COVID-19 infection Warm autoimmune hemolytic anemia associated with asymptomatic SARS-CoV-2 Infection Severe warm autoimmune hemolytic anemia in COVID-19 managed with least incompatible RBC product and glucocorticoids A 3-case series of autoimmune haemolytic anaemia and COVID-19: is plasma exchange an alternative? SN Compr Clin Med Is molecular mimicry the culprit in the autoimmune haemolytic anaemia affecting patients with COVID-19? Coronavirus-induced autoimmunity Risk of venous thromboembolism among hospitalizations of adults with selected autoimmune diseases Thrombotic complications in patients with immune-mediated hemolysis Autoimmune hemolytic anemia and pulmonary embolism: an association to consider Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease Prevalence of Venous Thromboembolism in Critically Ill COVID-19 Patients: Systematic Review and Meta-Analysis Prevalence, clinical manifestations, and biochemical data of type 2 diabetes mellitus versus nondiabetic symptomatic patients with COVID-19: A comparative study Prevalence, clinical manifestations, and biochemical data of hypertensive versus normotensive symptomatic patients with COVID-19: a comparative study